Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(8%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
1
8%
Ph phase_4
6
50%
Ph phase_1
1
8%
Ph phase_3
1
8%
Ph not_applicable
1
8%

Phase Distribution

1

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
6(60.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(5)
Terminated(1)
Other(4)

Detailed Status

Completed5
unknown4
Terminated1
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 21 (10.0%)
Phase 31 (10.0%)
Phase 46 (60.0%)
N/A1 (10.0%)

Trials by Status

completed542%
terminated18%
not_yet_recruiting18%
unknown433%
recruiting18%

Recent Activity

1 active trials
Showing 5 of 12
completed

Neuroimaging Ancillary Study

NCT05545527
not_yet_recruitingphase_4

Iron Isomaltoside for the Treatment of Anemia in Peritoneal Dialysis Patients

NCT06830941
recruitingphase_4

IV Iron-induced Hypophosphatemia After RYGB

NCT06350955
completedphase_4

Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial

NCT05358509
unknown

RAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study

NCT05504863
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05545527

Neuroimaging Ancillary Study

Completed
NCT06830941Phase 4

Iron Isomaltoside for the Treatment of Anemia in Peritoneal Dialysis Patients

Not Yet Recruiting
NCT06350955Phase 4

IV Iron-induced Hypophosphatemia After RYGB

Recruiting
NCT05358509Phase 4

Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial

Completed
NCT05504863

RAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study

Unknown
NCT03957057Phase 3

Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia

Completed
NCT05299411Phase 2

Intravenous Iron Infusion on Chemotherapy-induced Anemia

Unknown
NCT03610230Not Applicable

Iron Isomaltoside Compared With Iron Sucrosein Peritoneal Dialysis Patients

Terminated
NCT03466983Phase 4

A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

Completed
NCT04346004Phase 4

Effect of Preoperative Iron Isomaltoside 1000 Administration on Hemoglobin Concentration in Patients Undergoing Transcatheter Aortic Valve Implantation

Unknown
NCT03013439Phase 1

Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)

Completed
NCT02999217Phase 4

Intravenous Iron for Correction of Anaemia After Colorectal Surgery

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12